CG
ZYNE

Cutler Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Cutler Group’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-500
Closed -$1K – 6300
2021
Q4 		$1K Buy
+500
New +$1.85K ﹤0.01% 5241
2021
Q2 		– Sell
-600
Closed -$1K – 6581
2021
Q1 		$1K Buy
600
+100
+20% +$453 ﹤0.01% 5456
2020
Q4 		$1K Hold
500
– – ﹤0.01% 4662
2020
Q3 		$1K Sell
500
-700
-58% -$2.57K ﹤0.01% 4522
2020
Q2 		$2K Buy
1,200
+700
+140% +$3.31K ﹤0.01% 3887
2020
Q1 		$1K Sell
500
-2,300
-82% -$10.7K ﹤0.01% 3866
2019
Q4 		$10K Buy
2,800
+500
+22% +$3.42K ﹤0.01% 2671
2019
Q3 		$7K Sell
2,300
-300
-12% -$3.38K ﹤0.01% 2872
2019
Q2 		$7K Buy
2,600
+100
+4% +$1.15K ﹤0.01% 2944
2019
Q1 		$12K Hold
2,500
– – ﹤0.01% 2408
2018
Q4 		$18K Sell
2,500
-5,400
-68% -$29.6K ﹤0.01% 2192
2018
Q3 		$41K Buy
7,900
+2,700
+52% +$20.7K ﹤0.01% 1736
2018
Q2 		$29K Sell
5,200
-8,700
-63% -$89.2K ﹤0.01% 1961
2018
Q1 		$51K Sell
13,900
-8,200
-37% -$88.4K ﹤0.01% 1658
2017
Q4 		$37K Buy
22,100
+8,900
+67% +$102K ﹤0.01% 2103
2017
Q3 		$42K Sell
13,200
-7,100
-35% -$75.1K ﹤0.01% 2408
2017
Q2 		$81K Buy
20,300
+12,200
+151% +$243K ﹤0.01% 2049
2017
Q1 		$16K Buy
8,100
+3,900
+93% +$77.5K ﹤0.01% 3580
2016
Q4 		$4K Sell
4,200
-20,700
-83% -$279K ﹤0.01% 5176
2016
Q3 		$22K Buy
+24,900
New +$236K ﹤0.01% 3348

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cutler Group's ZYNE Position: Q1 2022 in Review

Cutler Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2022, closing a stake of 100 shares.

Cutler Group first reported a position in ZYNE in Q3 2016 and held it in 21 quarters. The position peaked at $186K in Q3 2018. 59 funds tracked by Wall St. Rank hold ZYNE as of Q1 2022.

  • Cutler Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2022 after selling out during the quarter.
  • Cutler Group sold 100 Zynerba Pharmaceuticals, Inc shares in Q1 2022.
  • Cutler Group first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2016 and held it in 21 quarters.
  • Cutler Group's Zynerba Pharmaceuticals, Inc position peaked at $186K in Q3 2018.
  • 59 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.